![]() ![]() Model-predicted decline in FEV 1 showed that, compared with 'no ongoing' therapy, initiation of triple or LAMA/LABA therapy at age 40, 55 or 65 years preserved an additional 469.7 mL or 236.0 mL, 327.5 mL or 203.3 mL, or 213.5 mL or 137.5 mL of lung function, respectively, by the age of 75. The model simulated decline in FEV 1 and annual exacerbation rates from age 40 to 75 years in COPD with initiation of long-acting anti-muscarinic antagonist (LAMA)/long-acting beta 2-agonist (LABA) (umeclidinium (UMEC)/vilanterol (VI)) or triple (inhaled corticosteroid (ICS)/LAMA/LABA fluticasone furoate (FF)/UMEC/VI) therapy at 40, 55 or 65 years of age. The modelling approach used data on decline in forced expiratory volume in 1 s (FEV 1) extracted from published studies to develop a longitudinal non-parametric superposition model of lung function decline with progressive impact of exacerbations from 0 per year to 3 per year and no ongoing pharmacotherapy. This predictive modelling study assessed the impact of initiating pharmacotherapy earlier versus later on long-term disease progression in COPD. studies demonstrate an accelerated decline in lung function in patients with moderate chronic obstructive pulmonary disease (COPD) (Global Initiative for Chronic Obstructive Lung Disease grade 2) versus severe and very severe COPD (GOLD grades 3 and 4). 12 Clinical Pharmacology and Experimental Medicine, GSK, Brentford, London, UK.1 Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. 10 Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.9 Value Evidence and Outcomes, GSK, Collegeville, PA, USA.8 Emerging Markets, GSK, Singapore, Singapore.7 Department of Botucatu Medical School, Universidade Estadual Paulista, São Paulo, Brazil.6 Department of Chest Diseases, Ege University Faculty of Medicine, İzmir, Turkey.5 Universidad Autónoma de Nuevo León, Servicio de Neumología, CIPTIR, Monterrey, NL, México.4 Universidad Anáhuac, Querétaro, México.3 Pulmonology Unit, Hospital General de Agudos Dr. ![]() 2 Manchester University NHS Foundation Trust, Manchester, UK.1 Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |